Suchergebnisse - "Terness, Peter"

PubPharm (140)

1

MIC THERAPY FOR SPECIFIC IMMUNOSUPPRESSION IN TRANSPLANTATION

enthalten in: Europäisches Patentamt | 2023

von MORATH CHRISTIAN | SCHMITT ANITA | SCHAIER MATTHIAS | +7

2

MIC THERAPY FOR SPECIFIC IMMUNOSUPPRESSION IN TRANSPLANTATION

enthalten in: Europäisches Patentamt | 2023

von MORATH CHRISTIAN | SCHMITT ANITA | SCHAIER MATTHIAS | +7

3

Five-year follow-up of a phase I trial of donor-derived modified immune cell infusion in kidney transplantation

enthalten in: Frontiers in immunology | 11 July 2023

von Schaier, M. | Morath, C. | Wang, L. | +38

4

Correction : Oweira et al. Kynurenine Is the Main Metabolite of Tryptophan Degradation by Tryptophan 2,3-Dioxygenase in HepaRG Tumor Cells. J. Clin. Med. 2022, 11, 4794

enthalten in: Journal of clinical medicine | 2023

von Oweira, H. | Lahdou, I. | Mehrle, S. | +7

ErratumFor: J Clin Med. 2022 Aug 16;11(16):. - PMID 36013032

5

Correction: Oweira et al. Kynurenine Is the main metabolite of tryptophan degradation by tryptophan 2,3-dioxygenase in HepaRG tumor cells. J. Clin. Med. 2022, 11, 4794

enthalten in: Journal of Clinical Medicine | 28 April 2023

von Oweira, H. | Lahdou, I. | Mehrle, S. | +7

6

MIC therapy for specific immunosuppression in transplantation

enthalten in: Europäisches Patentamt | 2023

von MORATH CHRISTIAN | SCHMITT ANITA | SCHAIER MATTHIAS | +7

7

MIC therapy for specific immunosuppression in transplantation

enthalten in: Europäisches Patentamt | 2023

von MORATH CHRISTIAN | SCHMITT ANITA | SCHAIER MATTHIAS | +7

8

Induction of Long-Lasting Regulatory B Lymphocytes by Modified Immune Cells in Kidney Transplant Recipients

enthalten in: Journal of the American Society of Nephrology : JASN | 2023

von Morath, C. | Schaier, M. | Ibrahim, E. | +30

CommentIn: J Am Soc Nephrol. 2023 Jan 1;34(1):4-7. - PMID 36719144

9

Five-year follow-up of a phase I trial of donor-derived modified immune cell infusion in kidney transplantation

enthalten in: Frontiers in immunology | 2023

von Schaier, M. | Morath, C. | Wang, L. | +38

10

Individualised immunosuppression with intravenously administered donor-derived modified immune cells compared with standard of care in living donor kidney transplantation (TOL-2 Study) : protocol for a multicentre, open-label, phase II, randomised controlled trial

enthalten in: BMJ open | 2022

von Morath, C. | Schmitt, A. | Schmitt, M. | +36

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[14]